Showing posts with label IMMUNOLOGY. Show all posts
Showing posts with label IMMUNOLOGY. Show all posts

Saturday, 15 April 2017

IMMUNOLOGY

Skin Test Wheal and Flare Mechanism: 
• Introduction of antigen into the skin causes local mast cell activation via cross-linking of preformed, antigen-specific, membrane-bound IgE.
• The release of preformed histamine from mast cells causes increased vascular permeability via smooth muscle contraction and development of wheal; inflammatory mediators initiate neural reflex vasodilation, leading to development of flare.

CLINICAL PEARLS 
• Skin testing is a practical, reliable, and well-tolerated method of establishing IgE-mediated disease. • Interpretation of skin testing should be done by an experienced practitioner, in the presence of positive and negative controls, and may be confounded by dermatographism or antihistamine use.
• The presence of a positive skin test documents the presence of allergen-specific IgE antibody. Diagnosis of allergy can be made only by correlating skin testing results with the presence of clinical symptoms.

Allergen immunotherapy: Definition, indication, and reactions

Specific allergen immunotherapy is the administration of increasing amounts of specific allergens to which the patient has type I immediate hypersensitivity. It is a disease modifying therapy, indicated for the treatment of allergic rhinitis, allergic asthma, and hymenoptera hypersensitivity. Specific IgE antibodies for appropriate allergens for immunotherapy must be documented. Indications for allergen immunotherapy include (1) inadequate symptom control despite pharmacotherapy and avoidance measures, (2) a desire to reduce the morbidity from allergic rhinitis and/or asthma or reduce the risk of anaphylaxis from a future insect sting, (3) when the patient experiences undesirable side effects from pharmacotherapy, and (4) when avoidance is not possible. Furthermore, patients may seek to benefit from economic savings of allergen immunotherapy compared with pharmacotherapy over time. Several studies have reported that immunotherapy in children with allergic rhinitis appears to prevent the development of new allergic sensitizations and/or new-onset asthma. Humoral, cellular, and tissue level changes occur with allergen immunotherapy including large increases in antiallergen IgG4 antibodies, a decrease in the postseasonal rise of antiallergen IgE antibodies, reduced numbers of nasal mucosal mast cells and eosinophils, induction of Treg cells, and suppression of Th2 more than Th1 lymphocytes. There is a corresponding increase in IL-10 and transforming growth factor beta. In the United States, allergen immunotherapy is administered by the subcutaneous route in the physician’s office, whereas primarily in some countries in Europe, it is administered for allergic rhinitis and asthma by the sublingual route by the patient at home.

Specific allergen immunotherapy, often called “allergy shots,” has been defined as the administration of increasing amounts of specific allergens to which the patient has type I immediate hypersensitivity. The purpose of allergen immunotherapy is to provide protection against the allergic symptoms and inflammatory reactions associated with natural exposure to these allergens. Although the single best marker that explains immunotherapy’s efficacy is unknown, there are many immunologic changes that occur with immunotherapy

INDICATION AND DURATION
 Immunotherapy is indicated for patients who have clinically significant IgE-mediated allergic rhinitis,asthma,4 and hymenoptera sensitivity.5 Specific IgE for appropriate allergens must be documented and symptoms should correlate with exposure to those specific allergens selected for immunotherapy.6–8 Other indications for allergen immunotherapy include inadequate symptom control despite pharmacotherapy and avoidance measures, undesirable side effects from pharmacotherapy, and when avoidance is not possible.In addition, immunotherapy may prevent the development of new sensitizations and/or new-onset asthma. The relative contraindications to allergen immunotherapy include severe or uncontrolled asthma, significant cardiovascular disease, and -blocker use.Immunotherapy is not currently approved for food allergy or chronic urticaria and/or angioedema. However, the most recent immunotherapy practice parameter suggests an expanded indication, atopic dermatitis in subjects with aeroallergen sensitization. Multiple controlled studies have shown that immunotherapy is effective treatment for allergic rhinitis due grass, ragweed, and birch pollen.Immunotherapy with house-dust mite vaccines is an effective treatment for both allergic asthma and allergic rhinitis. Studies favoring allergen immunotherapy in patients with asthma have been published for grasses, trees (birch),ragweed, cat, and fungi (Alternaria and Cladosporium).Patients with mild asthma are more likely to benefit from immunotherapy than patients with moderate or severe asthma who may be at increased risk for adverse reactions to immunotherapy. To appropriately choose allergens for cutaneous testing and immunotherapy, it is important to be familiar with the significant aeroallergens in a patient’s geographic location

Immunologic changes with immunotherapy

Antibody changes 
Increase in allergen-specific IgG (specifically IgG4) 
Early increase and late decrease in serum-specific IgE 
Decrease in seasonal rise of specific IgE 
Cellular changes 
Decreased mediator release from mast cells, 
basophils, and eosinophils 
Reduction of tissue mast cells and eosinophils 
Induction of regulatory T cells and suppression of Th2 Th1 cells 
Increased secretion of IL-10 and TGF- 
Decrease in histamine-releasing factors 

Saturday, 8 April 2017

DRUGS

Medicines often are implicated in triggering undesired immunologic reactions. True drug allergy represents 6 –10% of all adverse drug reactions and is overreported by individuals. Most drugs are too small (1000 Da) to incite allergic sensitization alone. To cause an allergic reaction, a reactive metabolite of the drug must bind to a macromolecular carrier for antigen processing. The drug metabolite in the carrier molecule complex is known as a hapten. This makes skin testing difficult for diagnostic accuracy. Large molecular weight drugs (heterologous antisera, insulin, streptokinase, and l-asparaginase), which are 4000 Da, and medicines that have enough distance between determinants to be bivalent (quaternary ammonium muscle relaxants and aminoglycosides), may provoke an allergic response without forming a hapten–protein complex. 

LATEX 
Natural rubber latex is a product of the rubber tree Hevea brasilensis. Sensitization is present in 75% of patients with spina bifida and 6.5% of the general population. Health care providers and patients with urological problems requiring catherization are also at increased risk. Clinical manifestations of IgE-mediated disease include allergic rhinitis, asthma, contact urticaria, and anaphylaxis. The incidence of IgE-mediated reactions to latex has declined mostly because of the development of powder-free, low-protein gloves. 

INGESTED ALLERGENS 
Food allergy is common and appears to be increasing; it can be divided into class 1 and class 2. Class 1 food allergy is considered “traditional” and occurs in the gastrointestinal tract. Class 2 food allergy is caused by allergic sensitization to inhalant allergens that cross-react with food allergens. Class 1 allergens are 10 –70 kDa and are heat, acid, and protease stable. Common class 1 allergens are cow’s milk, chicken egg, peanut, soybean, fish, and shrimp. Thirty-five percent of children with moderate to severe atopic dermatitis have an associated food allergy,15 and 6% of asthmatic children have associated food allergy. Peanut is the most common food allergy in individuals 4 years old. There has been a dramatic increase in the number of children with peanut allergy with one study noting peanut allergy prevalence of 1.4% in 2008 versus 0.8% in 2002 in the United States. Studies are currently looking at environmental factors that may result in this increased prevalence. 

Cross-reactivity between members of a food allergen group varies. Cross-reactivity between peanuts and other legumes is 5%, between tree nuts 35%, between different fish 50%, and 75% between members of the shellfish family. Cross-reactivity also occurs between aeroallergens and certain food allergy resulting in class 2 food allergies. This is known as pollen–food syndrome (previously oral allergy syndrome) and manifests as pruritus with or without angioedema of the lips, tongue, palate, and posterior oropharynx. Shared allergen sensitivities have been reported between ragweed and the gourd family (watermelon, cantaloupe, zucchini, and cucumbers) and bananas. Birch pollen shares allergen sensitivities with apples, carrots, parsnips, celery, hazelnuts, potatoes, celery, and kiwi. Tree and grass pollen share allergens with apples, tree nuts, peaches, oranges, pears, cherries, fennel, tomatoes, and carrots. Often, cooking or peeling these foods reduces symptoms of pollen–food syndrome.

Reviewing the properties of common allergens reinforces the foundation of controlling clinical allergy symptoms, which is avoidance of allergen exposure. Their properties also form the basis for developing diagnostic and therapeutic opportunities.

IMMUNOLOGY
 • An allergen is typically a protein or glycoprotein that can induce an IgE-mediated immune response with an associated clinical reaction. 
 • Size of pollen determines clinical manifestation of allergy. Particles between 20 and 60 m in diameter can be carried in the wind and cause nasal and ocular symptoms. Particles 7 m can deposit in the airways and cause symptoms of asthma. 
• True drug allergy represents 6 –10% of all adverse drug reactions. Skin testing is difficult because most drug allergens are small metabolites of the implicated drug and they must haptenize a carrier protein to induce an immune response. 

CLINICAL PEARLS
 • Most tree pollens do not have significant cross-reactivity and are released in the spring in the United States. In the upper midwestern United States, tree pollination occurs in mid to late March until May. 
• Grass pollen comes from the Poaceae family, has significant cross-reactivity, and is typically released in the late spring and early summer in the United States. In the upper midwestern United States, this time is from mid-May to the end of July. 
• Weed pollens are released mostly in the autumn in the United States with ragweed being the major allergen from August 15 to October 1 in the upper midwestern United States. 
• Global warming has shifted the floristic zones in North America to higher latitudes. Ragweed has increased in size and pollen production because of increased CO2 and temperature. 
• Fungal spores and mycelial elements are released preferentially in warm, humid environments. The first hard frost of late autumn decreases outdoor mold spores. 
• Dust mites thrive in warm, humid conditions and provide allergen through their fecal particles, enhanced by intrinsic enzymic activity. 
• Cat allergen may last in a home for up to 6 months after the source is removed. It can be isolated from saliva, urine, dander, and from sebaceous glands.
• The most common class I food allergens are cow’s milk, chicken egg, peanut, soybean, fish, and shrimp. There has been an increase in the prevalence of peanut allergy in children. 
• Pollen–food syndrome occurs because of cross-reactivity between aeroallergens and certain food proteins.